Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s150, 2023. DOI: 10.25251/skin.7.supp.150. Disponível em: https://skin.dermsquared.com/skin/article/view/1989. Acesso em: 19 apr. 2025.